GHRP-2 vs GHRP-6: Growth Hormone Release, Appetite, and Side Effects Compared

GHRP-2 vs GHRP-6 is a comparison between two of the earliest synthetic growth hormone releasing peptides (GHRPs). Both are hexapeptides that activate the ghrelin receptor to release growth hormone, and both pre-date the more selective agents clinicians tend to reach for today. They differ in potency, in how strongly they stimulate appetite, and in their effects on cortisol and prolactin. This guide compares GHRP-6 and GHRP-2 directly and explains where they sit relative to ipamorelin and hexarelin.

Educational content for licensed healthcare professionals. Not medical advice; dosing and treatment decisions belong to the prescribing clinician.

GHRP-2 vs GHRP-6 at a Glance

Where These Peptides Came From

GHRP-6 was one of the first synthetic peptides shown to release growth hormone, developed in the early 1980s — before the ghrelin receptor it acts on had been identified. Work on its mechanism contributed to the later discovery of the growth hormone secretagogue receptor and, eventually, of ghrelin itself. GHRP-2 followed as a more potent analogue. Both belong to the same family as hexarelin and ipamorelin.

Shared Mechanism

Both peptides bind GHS-R1a, the ghrelin receptor:

• In the pituitary, activation releases growth hormone through a calcium-dependent pathway independent of the GHRH receptor.
• In the hypothalamus, they increase GHRH release and reduce somatostatin's inhibitory tone.

Because this pathway is separate from GHRH signaling, both GHRPs act synergistically with GHRH analogues such as sermorelin or CJC-1295 — the same principle behind the CJC-1295 + ipamorelin combination.

GHRP-6: Strong Appetite Effect

The defining feature of GHRP-6 is hunger. Ghrelin is the body's principal hunger signal, and GHRP-6 reproduces that effect strongly, with increased appetite shortly after dosing. That is a drawback for most patients focused on body composition, and it is why GHRP-6 has sometimes been considered where appetite stimulation is actually wanted.

GHRP-2: More Potent, Less Hungry

GHRP-2 is the more potent GH secretagogue of the two, and its appetite effect is generally less pronounced. It raises cortisol and prolactin — endocrine effects that are part of why more selective agents were developed. Its use in Japan as a diagnostic agent for assessing GH secretory capacity reflects its reliable, strong GH response.

Shared Drawbacks

• Cortisol and prolactin increases. Both GHRPs raise these hormones, unlike ipamorelin, which showed minimal effect in preclinical studies.
• Desensitization. Repeated, frequent dosing of potent GHRPs can blunt the GH response over time, a phenomenon well described for hexarelin.
• GH-related effects. Water retention, joint aches, hand tingling, and reduced insulin sensitivity can occur when GH and IGF-1 run high.
• Limited long-term data. Neither has a body of long-term outcome trials in adults.

Practical Considerations

Desensitization and Scheduling

Potent ghrelin-receptor agonists can lose effect with frequent, continuous use as the receptor and downstream signaling adapt. This is one reason protocols using GHRPs have often included breaks, and one reason clinicians track IGF-1 over time rather than assuming a stable response.

Pairing With a GHRH Analogue

GHRPs and GHRH analogues act through different receptors, so pairing them produces a larger GH pulse than either alone. The same pairing logic applies whether the GHRP is GHRP-2, GHRP-6, or ipamorelin; the choice of GHRP mainly changes the appetite and cortisol profile.

Appetite as a Clinical Variable

For most body-composition goals, GHRP-6's hunger effect works against the patient. In settings where appetite stimulation is the goal, such as unintended weight loss, it has been viewed differently. That makes the GHRP-2 vs GHRP-6 choice partly a question of whether hunger is a side effect or a target.

Monitoring

Monitoring follows the same pattern as other GH-axis therapy: baseline and follow-up IGF-1, glucose markers, and attention to fluid retention, joint symptoms, and hand tingling. Because both GHRPs raise prolactin, symptoms such as breast tenderness warrant evaluation.

How Both Compare With Ipamorelin

This profile is why ipamorelin has largely become the default ghrelin-receptor agonist in clinical protocols: it trades some potency for cleaner selectivity, and it has a clearer compounding position.

Regulatory Status

Neither GHRP-2 nor GHRP-6 is an FDA-approved drug, and neither appears on our FDA peptide status tracker. Prescribers considering either should confirm compounding eligibility with their compounding partner. Both are prohibited at all times under the WADA Prohibited List.

The GHRP-2 Matrix formulation is a separate multi-ingredient product; that post covers the product itself.

Where These Fit

GHRP-2 and GHRP-6 are two of several growth hormone peptides. How they compare with GHRH analogues, ipamorelin, oral secretagogues like MK-677, and IGF-1 analogues is covered in our hub on peptides for muscle growth. Newtropin connects licensed providers with a licensed 503A compounding partner; prescribers can start at For Providers.

Frequently Asked Questions

What is the difference between GHRP-2 and GHRP-6?

Both are hexapeptides that activate the ghrelin receptor to release growth hormone. GHRP-2 is more potent for GH release and stimulates appetite less; GHRP-6 produces strong hunger.

What is GHRP-6?

GHRP-6 is a synthetic six-amino-acid growth hormone releasing peptide, one of the first discovered. It activates the ghrelin receptor and is known for strong appetite stimulation.

What is GHRP-2?

GHRP-2, also called pralmorelin, is a synthetic hexapeptide growth hormone secretagogue. It is more potent than GHRP-6 and has been used in Japan as a diagnostic agent for GH deficiency.

Which is better, GHRP-2 or GHRP-6?

It depends on the goal. GHRP-2 is generally preferred where appetite stimulation is unwanted; GHRP-6 where it is acceptable or desired. Many clinicians prefer ipamorelin to both for its selectivity.

Do GHRP-2 and GHRP-6 raise cortisol?

Yes. Both increase cortisol and prolactin to some degree, unlike ipamorelin, which showed minimal effect in preclinical studies.

Are GHRP-2 and GHRP-6 FDA-approved?

No. Neither is an FDA-approved drug, and neither appears on our FDA status tracker. Both are prohibited in competitive sport.